This research introduces SWIFT-seq, a novel single-cell sequencing workflow designed to monitor multiple myeloma through a simple blood draw. By analyzing circulating tumor cells (CTCs), the method provides a noninvasive alternative to painful bone marrow biopsies, which are often difficult to perform frequently. The study demonstrates that SWIFT-seq accurately identifies cytogenetic abnormalities and measures tumor proliferation using as few as ten cells. It further establishes a circulatory capacity signature that explains how specific genetic traits drive cancer cells into the bloodstream. Ultimately, this technology captures the genomic complexity and clonal dynamics of the disease, offering a powerful tool for routine clinical surveillance and improved patient prognostication.

References:

• Lightbody E D, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors[J]. Nature Cancer, 2025, 6(9): 1595-1611.